REGN vs. SNY
Compare and contrast key facts about Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: REGN or SNY.
Correlation
The correlation between REGN and SNY is 0.48, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
REGN vs. SNY - Performance Comparison
Loading data...
Key characteristics
REGN:
-1.26
SNY:
0.35
REGN:
-1.83
SNY:
0.53
REGN:
0.77
SNY:
1.06
REGN:
-0.71
SNY:
0.27
REGN:
-1.24
SNY:
0.60
REGN:
32.21%
SNY:
9.63%
REGN:
32.01%
SNY:
24.40%
REGN:
-91.81%
SNY:
-46.65%
REGN:
-51.26%
SNY:
-10.61%
Fundamentals
REGN:
$61.69B
SNY:
$121.71B
REGN:
$39.33
SNY:
$2.77
REGN:
14.53
SNY:
17.77
REGN:
1.24
SNY:
0.82
REGN:
4.38
SNY:
2.69
REGN:
2.11
SNY:
1.46
REGN:
$14.09B
SNY:
$43.77B
REGN:
$11.96B
SNY:
$31.12B
REGN:
$4.98B
SNY:
$9.61B
Returns By Period
In the year-to-date period, REGN achieves a -17.77% return, which is significantly lower than SNY's 10.13% return. Over the past 10 years, REGN has underperformed SNY with an annualized return of 1.67%, while SNY has yielded a comparatively higher 4.18% annualized return.
REGN
-17.77%
4.85%
-25.15%
-40.12%
0.31%
1.67%
SNY
10.13%
4.97%
11.07%
8.37%
5.62%
4.18%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
REGN vs. SNY — Risk-Adjusted Performance Rank
REGN
SNY
REGN vs. SNY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
REGN vs. SNY - Dividend Comparison
REGN's dividend yield for the trailing twelve months is around 0.15%, less than SNY's 4.35% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceuticals, Inc. | 0.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SNY Sanofi | 4.35% | 4.22% | 3.83% | 4.22% | 3.80% | 3.61% | 3.46% | 4.29% | 3.67% | 4.03% | 3.79% | 4.19% |
Drawdowns
REGN vs. SNY - Drawdown Comparison
The maximum REGN drawdown since its inception was -91.81%, which is greater than SNY's maximum drawdown of -46.65%. Use the drawdown chart below to compare losses from any high point for REGN and SNY. For additional features, visit the drawdowns tool.
Loading data...
Volatility
REGN vs. SNY - Volatility Comparison
Regeneron Pharmaceuticals, Inc. (REGN) has a higher volatility of 17.09% compared to Sanofi (SNY) at 8.38%. This indicates that REGN's price experiences larger fluctuations and is considered to be riskier than SNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
REGN vs. SNY - Financials Comparison
This section allows you to compare key financial metrics between Regeneron Pharmaceuticals, Inc. and Sanofi. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
REGN vs. SNY - Profitability Comparison
REGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.56B and revenue of 3.03B. Therefore, the gross margin over that period was 84.7%.
SNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Sanofi reported a gross profit of 7.72B and revenue of 10.61B. Therefore, the gross margin over that period was 72.8%.
REGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Regeneron Pharmaceuticals, Inc. reported an operating income of 591.70M and revenue of 3.03B, resulting in an operating margin of 19.5%.
SNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Sanofi reported an operating income of 2.29B and revenue of 10.61B, resulting in an operating margin of 21.5%.
REGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Regeneron Pharmaceuticals, Inc. reported a net income of 808.70M and revenue of 3.03B, resulting in a net margin of 26.7%.
SNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Sanofi reported a net income of 1.87B and revenue of 10.61B, resulting in a net margin of 17.7%.